On February 12th 2019 the FDA Advisory Committee Recommend the Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression. The committees based their support on the safety and efficacy data from five Phase 3 studies in patients with treatment-resistant depression: three short-term studies; one maintenance of effect study; and one long-term safety study. In addition, the SPRAVATOTM research program provided supportive data from three Phase 2 studies and 19 Phase 1 studies in patients with treatment-resistant depression and healthy volunteers.
With the FDA approval of Spravato, the medical community has even more confirmation in the ability of the Ketamine molecule to provide substantial and rapid relief. Ketamine has been found to relieve the symptoms of depression within hours, rather than the usual weeks most antidepressants can take. If you or a loved one has questions or is struggling with depression we would like to invite you to contact us and schedule a free consultation to learn more about how Ketamine infusion therapy may be able to help.
Request a Free Phone Consultation
Call us today for a free phone consultation with a member of our administrative staff or fill out the form below and a member of our team will get right back to you.